We are live on ! Find out more
EW icon

Edwards Lifesciences

1,279 hedge funds and large institutions have $46.6B invested in Edwards Lifesciences in 2024 Q1 according to their latest regulatory filings, with 159 funds opening new positions, 436 increasing their positions, 462 reducing their positions, and 106 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more funds holding in top 10

Funds holding in top 10: 914 (+5)

50% more first-time investments, than exits

New positions opened: 159 | Existing positions closed: 106

25% more capital invested

Capital invested by funds: $37.3B → $46.6B (+$9.28B)

3% more funds holding

Funds holding: 1,2441,279 (+35)

10% more call options, than puts

Call options by funds: $431M | Put options by funds: $393M

0.75% more ownership

Funds ownership: 80.51%81.25% (+0.75%)

6% less repeat investments, than reductions

Existing positions increased: 436 | Existing positions reduced: 462

Holders
1,279
Holders Change
+35
Holders Change %
+2.81%
% of All Funds
18.42%
Holding in Top 10
14
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+55.56%
% of All Funds
0.2%
New
159
Increased
436
Reduced
462
Closed
106
Calls
$431M
Puts
$393M
Net Calls
+$38.1M
Net Calls Change
-$65.8M
Name Holding Trade Value Shares
Change
Change in
Stake
BAM
251
Bell Asset Management
Australia
$12.2M -$4.12M -49,017 -28%
MIF
252
Mediolanum International Funds
Ireland
$12.2M +$10.7M +127,830 New
LGWM
253
Litman Gregory Wealth Management
California
$12.1M -$5.88K -70 -0.1%
BBVA
254
Banco Bilbao Vizcaya Argentaria
Spain
$12M -$1.64M -19,569 -13%
AT
255
AMF Tjänstepension
Sweden
$12M -$5.99M -71,305 -36%
TPSF
256
Texas Permanent School Fund
Texas
$12M +$12.3K +146 +0.1%
SMDAM
257
Sumitomo Mitsui DS Asset Management
Japan
$11.8M -$69.9K -832 -0.7%
CIBC Asset Management
258
CIBC Asset Management
Ontario, Canada
$11.6M +$550K +6,550 +6%
LWCFA
259
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$11.6M -$4.42M -52,589 -28%
GCM
260
Genus Capital Management
British Columbia, Canada
$11.5M +$10.1M +119,929 New
FAF
261
Fjarde Ap-fonden
Sweden
$11.3M -$571K -6,800 -5%
UB
262
UMB Bank
Missouri
$11.2M +$3.96M +47,130 +67%
CAM
263
Congress Asset Management
Massachusetts
$11.1M +$8.4K +100 +0.1%
FC
264
Fulcrum Capital
Washington
$10.9M +$40.2K +479 +0.4%
JC
265
Jacobs & Co
California
$10.8M +$178K +2,116 +2%
TAM
266
Trillium Asset Management
Massachusetts
$10.6M +$43.6K +519 +0.5%
JFG
267
Jefferies Financial Group
New York
$10.5M -$5.77M -68,726 -39%
JSP
268
Jackson Square Partners
California
$10.5M -$717K -8,533 -7%
MML Investors Services
269
MML Investors Services
Massachusetts
$10.3M -$1.25M -14,830 -12%
AIMCA
270
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$10.3M
Osaic Holdings
271
Osaic Holdings
Arizona
$10.2M -$8.32M -99,052 -48%
EDRH
272
Edmond de Rothschild Holding
Switzerland
$10.2M +$892K +10,613 +11%
SGA
273
Sector Gamma AS
Norway
$10.2M -$6.78M -80,690 -43%
CNB
274
Czech National Bank
Czech Republic
$10.2M +$41.1K +489 +0.5%
Teacher Retirement System of Texas
275
Teacher Retirement System of Texas
Texas
$10.2M +$1.49M +17,711 +20%

EW Hedge Fund Activity: Q1 2024 in Review

1,279 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q1 2024, worth a combined $46.6B — up 25% from $37.3B a quarter earlier.

Buyers outnumbered sellers: 159 funds opened new EW positions and 106 closed out — a net gain of 53 holders — while 436 added to existing stakes and 462 trimmed.

The largest buyer was Winslow Capital Management, opening a new position worth an estimated $425M. The largest seller was Capital International Investors, cutting an estimated $573M.

  • 1,279 institutional investors held Edwards Lifesciences (EW) as of Q1 2024, up from 1,244 in Q4 2023.
  • Funds reported $46.6B of Edwards Lifesciences stock for Q1 2024, up 25% quarter-over-quarter.
  • 159 funds opened new Edwards Lifesciences positions in Q1 2024 and 106 closed out, a net change of +53 holders.
  • The largest Edwards Lifesciences buyer in Q1 2024 was Winslow Capital Management, an estimated $425M added.
  • The largest Edwards Lifesciences seller in Q1 2024 was Capital International Investors, an estimated $573M sold.

Based on aggregated 13F filings for Q1 2024.